Real‐world effects of beremagene geperpavec in epidermolysis bullosa

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a severe inherited skin fragility disorder caused by mutations in COL7A1, leading to wounds, inflammation and impaired quality of life. Beremagene geperpavec (B-VEC) is the first approved topical gene therapy delivering functional COL7A1 via a modified HSV-1 vector, enabling local collagen VII expression and improved wound healing. OBJECTIVES: To evaluate the real-world, multidimensional long-term outcomes of B-VEC treatment in patients with DEB, including wound healing, systemic inflammation, (auto)-antibody profiles and patient-reported outcomes. METHODS: In this multicentre observational study, 38 patients with DEB received B-VEC treatment between January 2024 and June 2026. The primary endpoint was the change in wound surface area from baseline during B-VEC treatment. Secondary endpoints included changes in systemic inflammatory and haematological parameters [C-reactive protein (CRP), interleukin-6 (IL-6), serum amyloid A (SAA), leucocytes and haemoglobin (Hb)], (auto-)antibody profiles [anti-C7, BP180, BP230 and herpes simplex virus (HSV)-1/2 IgG], body mass index (BMI) and patient-reported outcomes, including pain, pruritus, treatment satisfaction and wound dressing time. RESULTS: B-VEC treatment was associated with a significant reduction in wound surface area across healing wounds. Patients having persistent wounds exhibited lower BMI and higher leucocyte counts and received systemic biologic therapies less frequently. Anti-BP180, BP230 and HSV-1/2 titres remained stable, while anti-C7 levels increased during treatment. IIF was negative in most patients and did not differ between groups. Systemic inflammation showed a mixed pattern, with reduced leucocyte counts and SAA levels, and slightly increased CRP and IL-6 under treatment. Hb and BMI increased during treatment. Most patients reported high treatment satisfaction and reduction in pain, pruritus and wound dressing time. CONCLUSIONS: B-VEC therapy provides clinically meaningful improvements in wound healing, patient-reported outcomes and selected systemic parameters in DEB. Treatment response is influenced by host factors such as BMI, systemic inflammation and concomitant therapies. Baseline (auto)-antibody profiles do not appear to predict treatment efficacy. Overall, B-VEC represents a significant advancement in the multidimensional management of DEB in real-world clinical practice.

Authors

Institutions

Publication Details

Journal
Journal of the European Academy of Dermatology and Venereology
Published
2026-11-12
DOI
https://doi.org/10.1111/jdv.70839
Primary Topic
Skin and Cellular Biology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‐world effects of beremagene geperpavec in epidermolysis bullosa

Robin Frank, Meropi Karakioulaki, Stella Gewert, Moritz Hess et al.
Journal of the European Academy of Dermatology and Venereology
Skin and Cellular Biology Research
article

Real‐world effects of beremagene geperpavec in epidermolysis bullosa

Robin Frank, Meropi Karakioulaki, Stella Gewert, Moritz Hess, Hanning Yang, Margret Pohl, Oliver Storz, Miodrag Davidovic, Cristina Has, Kilian Eyerich, Anna Luisa Hartmann, Nikolaos Stavropoulos, Nora Hummel
article en

Abstract

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a severe inherited skin fragility disorder caused by mutations in COL7A1, leading to wounds, inflammation and impaired quality of life. Beremagene geperpavec (B-VEC) is the first approved topical gene therapy delivering functional COL7A1 via a modified HSV-1 vector, enabling local collagen VII expression and improved wound healing. OBJECTIVES: To evaluate the real-world, multidimensional long-term outcomes of B-VEC treatment in patients with DEB, including wound healing, systemic inflammation, (auto)-antibody profiles and patient-reported outcomes. METHODS: In this multicentre observational study, 38 patients with DEB received B-VEC treatment between January 2024 and June 2026. The primary endpoint was the change in wound surface area from baseline during B-VEC treatment. Secondary endpoints included changes in systemic inflammatory and haematological parameters [C-reactive protein (CRP), interleukin-6 (IL-6), serum amyloid A (SAA), leucocytes and haemoglobin (Hb)], (auto-)antibody profiles [anti-C7, BP180, BP230 and herpes simplex virus (HSV)-1/2 IgG], body mass index (BMI) and patient-reported outcomes, including pain, pruritus, treatment satisfaction and wound dressing time. RESULTS: B-VEC treatment was associated with a significant reduction in wound surface area across healing wounds. Patients having persistent wounds exhibited lower BMI and higher leucocyte counts and received systemic biologic therapies less frequently. Anti-BP180, BP230 and HSV-1/2 titres remained stable, while anti-C7 levels increased during treatment. IIF was negative in most patients and did not differ between groups. Systemic inflammation showed a mixed pattern, with reduced leucocyte counts and SAA levels, and slightly increased CRP and IL-6 under treatment. Hb and BMI increased during treatment. Most patients reported high treatment satisfaction and reduction in pain, pruritus and wound dressing time. CONCLUSIONS: B-VEC therapy provides clinically meaningful improvements in wound healing, patient-reported outcomes and selected systemic parameters in DEB. Treatment response is influenced by host factors such as BMI, systemic inflammation and concomitant therapies. Baseline (auto)-antibody profiles do not appear to predict treatment efficacy. Overall, B-VEC represents a significant advancement in the multidimensional management of DEB in real-world clinical practice.

Journal of the European Academy of Dermatology and Venereology
University of Freiburg (DE), University Medical Center Freiburg (DE), St. Josef-Hospital (DE)
Good health and well-being
Skin and Cellular Biology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon